miR-375 Biomarker Assessment for Migraine Subtype Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing migraine and distinguishing between chronic and episodic migraine lack biomarkers, relying solely on headache frequency, which is inadequate for accurate differentiation.
Innovation Solution
An in vitro method utilizing the assessment of miR-375 expression levels in biological samples, optionally combined with other miRNAs and MRI parameters, particularly the surface area of the right superior frontal gyrus, to diagnose and differentiate between chronic and episodic migraine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If diagnosis is based solely on headache frequency, then the diagnostic method is simple, but the diagnostic accuracy is insufficient
Solution Approach 1:
The patent combines multiple diagnostic parameters including miR-375 expression levels, other miRNA profiles, and MRI parameters into a comprehensive diagnostic method. This merging of biomarkers and imaging data improves diagnostic accuracy for migraine and differentiation between chronic and episodic migraine types, resolving the contradiction between simple methodology and accurate diagnosis.
2Measurement precision
If current diagnostic criteria are used (headache days per month), then the diagnostic approach is easy to implement, but the ability to differentiate between migraine types is inadequate
Solution Approach 1:
The patent introduces miR-375 as an intermediary biomarker that mediates the differentiation between migraine types. This molecular marker serves as a bridge between simple clinical observation and accurate migraine classification, enabling distinction between chronic and episodic migraine through quantifiable expression levels while maintaining relative ease of implementation through blood sample analysis.
3Reliability
If multiple biomarkers and MRI parameters are combined, then the diagnostic capacity is improved, but the complexity of the assessment increases
Solution Approach 1:
The patent segments the diagnostic assessment into distinct components: miR-375 expression level assessment, other miRNA profile analysis, and MRI parameter evaluation. This segmentation allows each component to be evaluated independently and then integrated, improving diagnostic reliability through comprehensive assessment while managing complexity through structured, modular evaluation of each biomarker and imaging parameter separately.
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention refers to the medical field. Particularly, the present invention refers to an in vitro method for the diagnosis of migraine which comprises based on the assessment of the expression level of miR-375 in a biological sample obtained from a subject. It also refers to an in vitro method for the differential diagnosis of chronic and episodic migraine based on the assessment of the expression level of miR-375 in a biological sample obtained from a subject. It also refers to the in vitro use of the expression level of miR-375 for the diagnosis of migraine, or for the differential diagnosis of chronic and episodic migraine. In a preferred embodiment, the assessment of the expression level of miR-375 is combined with the assessment of other miRNAs or MRI parameters.